1775 Tysons Blvd
McLean, VA 22102
Stop-Loss Carriers and Captive
Stop-Loss Underwriting, Powered by Clinical Intelligence
See risk earlier. Price with confidence. Underwrite with precision.
Traditional stop-loss underwriting relies heavily on claims data—often incomplete, delayed, and missing critical clinical context. That gap leads to mispriced risk, unexpected high-cost claims, and unnecessary reserve padding.
MedShare CI changes that.
By delivering real clinical intelligence before underwriting and renewal decisions are made, MedShare CI gives stop-loss carriers and captives a clearer, more defensible view of member risk—so you can price accurately, act earlier, and reduce surprises.
The Problem with Claims-Only Underwriting
Claims data tells you what already happened—not what’s actively driving future risk.
Without clinical visibility, underwriting teams face:
- Incomplete or inaccurate diagnosis disclosures
- Limited insight into treatment activity and severity
- High-cost conditions that emerge too late
- Increased exposure to shock claims
- Conservative pricing driven by uncertainty
The result: missed risk, overcorrection, or both.
A More Complete View of Risk
Underwrite with clinical precision—not assumptions
MedShare CI aggregates permissioned clinical data from connected healthcare sources to give underwriting teams a deeper, more timely understanding of member health status.
With MedShare CI, you can:
- Validate diagnoses with clinical evidence
Confirm whether disclosed conditions are actively supported and treated - Identify treatment patterns that signal severity
Detect ongoing therapies that indicate rising cost risk - Surface high-cost exposures earlier
See what claims haven’t revealed yet - Improve laser accuracy and risk selection
Apply precision where it matters most - Reduce reliance on conservative pricing assumptions
Replace uncertainty with actionable insight
Identify High-Cost Risk Before It Hits
MedShare CI helps underwriting teams proactively detect members with clinical patterns associated with large future claims, including:
- Chemotherapy and oncology treatment
- Transplant cases
- Dialysis
- Specialty biologics
- Neonatal intensive care (NICU) risk
Instead of reacting to claims, you can anticipate cost drivers and act earlier.
How MedShare CI Supports Stop-Loss Underwriting
MedShare CI equips carriers and captives with the clinical intelligence needed to strengthen underwriting decisions at every stage:
- Pre-binding risk assessment
- Diagnosis validation
- Treatment-level visibility
- Renewal strategy optimization
- Risk segmentation and case identification
This allows underwriting teams to move beyond retrospective data and toward a forward-looking view of risk.
Real-World Example
A stop-loss carrier is evaluating a self-funded employer group for renewal.
Claims data shows limited high-cost activity. On the surface, the risk appears stable.
MedShare CI reveals a different story:
- Active dialysis treatment
- A recent oncology regimen
- A neonatal case with elevated NICU risk
With this visibility, the underwriting team can:
- Accurately assess future exposure
- Apply targeted laser strategies
- Avoid underpricing high-risk members
No surprises. No blind spots.
Business Impact
With MedShare CI, stop-loss carriers and captives can:
-
Improve underwriting accuracy
-
Reduce exposure to shock claims
-
Strengthen pricing and reserve discipline
-
Increase confidence in renewal decisions
-
Differentiate with clinically informed underwriting
-
Improve underwriting accuracy
-
Reduce exposure to shock claims
-
Strengthen pricing and reserve discipline
-
Increase confidence in renewal decisions
-
Differentiate with clinically informed underwriting
Bring Clinical Precision to Stop-Loss Underwriting
Stop relying on incomplete claims history to make high-stakes decisions.
MedShare CI gives you the clinical intelligence needed to underwrite with clarity, precision, and confidence—before risk becomes cost.